Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  49 results for ""GLUCAGON-like peptides""

Your Filters

Geographic : japan
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Adherence and treatment discontinuation of oral semaglutide and once-weekly semaglutide injection at 12 month follow-up: Japanese real-world data.

  • Authors : Horii T; Department of Pharmacy, Faculty of Pharmacy, Musashino University, Tokyo, Japan.; Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Saitama, Japan.

Subjects: Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/administration & dosage ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/therapeutic use ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy

  • Source: Journal of diabetes investigation [J Diabetes Investig] 2024 Nov; Vol. 15 (11), pp. 1578-1584. Date of Electronic Publication: 2024 Sep 07.Publisher: Asian Association for the Study of Diabetes and Blackwell Pub. Asia Country of Publication: Japan NLM ID: 101520702

Record details

Read More Add to Saved list
×
Academic Journal

PIONEER REAL Japan: Primary results from a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice.

  • Authors : Yabe D; Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.; Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/administration & dosage ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/adverse effects

  • Source: Journal of diabetes investigation [J Diabetes Investig] 2024 Nov; Vol. 15 (11), pp. 1566-1577. Date of Electronic Publication: 2024 Aug 22.Publisher: Asian Association for the Study of Diabetes and Blackwell Pub. Asia Country of Publication: Japan NLM ID: 101520702

Record details

Read More Add to Saved list
×
Academic Journal

Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching.

  • Authors : Iwamoto H; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.; Kimura T

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/blood ; Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Oct; Vol. 26 (10), pp. 4366-4374. Date of Electronic Publication: 2024 Jul 22.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Semaglutide improves treatment satisfaction and eating behaviour in Japanese patients with type 2 diabetes mellitus.

  • Authors : Baba Y; Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital, Chiba, Japan.; Watanabe S

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/therapeutic use ; Hypoglycemic Agents*/Hypoglycemic Agents*/Hypoglycemic Agents*/therapeutic use

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Oct; Vol. 26 (10), pp. 4787-4790. Date of Electronic Publication: 2024 Aug 02.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan.

  • Authors : Suzuki R; Department of Diabetes, Metabolism, and Endocrinology, Tokyo Medical University, Tokyo, Japan.; Amadid H

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/administration & dosage ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/therapeutic use

  • Source: Journal of diabetes investigation [J Diabetes Investig] 2024 Aug; Vol. 15 (8), pp. 1047-1056. Date of Electronic Publication: 2024 May 06.Publisher: Asian Association for the Study of Diabetes and Blackwell Pub. Asia Country of Publication: Japan NLM ID: 101520702

Record details

Read More Add to Saved list
×
Academic Journal

A randomized, double-blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD-JPN).

  • Authors : Morioka T; Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.; Takeuchi M

Subjects: Blood Glucose*/Blood Glucose*/Blood Glucose*/drug effects ; Blood Glucose*/Blood Glucose*/Blood Glucose*/metabolism ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Aug; Vol. 26 (8), pp. 3167-3175. Date of Electronic Publication: 2024 May 07.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Japan initiates market authorization of weight-loss drug semaglutide under universal health coverage, but with stringent prescription restrictions.

  • Authors : Hakariya H; Interfaculty Institute of Biochemistry, University of Tuebingen, Tuebingen, Germany.; Institute for Pharmaceutical and Social Health Sciences, Kyoto, Japan.

Subjects: Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/therapeutic use ; Universal Health Insurance*; Humans

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Aug; Vol. 26 (8), pp. 3006-3008. Date of Electronic Publication: 2024 May 15.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study).

  • Authors : Furusawa S; Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.; Nomoto H

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/blood ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/administration & dosage

  • Source: Endocrine journal [Endocr J] 2024 Jun 18; Vol. 71 (6), pp. 603-616. Date of Electronic Publication: 2024 Apr 25.Publisher: Japan Endocrine Society Country of Publication: Japan NLM ID: 9313485 Publication Model:

Record details

Read More Add to Saved list
×
Academic Journal

Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.

  • Authors : Tanaka K; First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan.; Okada Y

Subjects: Glycemic Control*/Glycemic Control*/Glycemic Control*/adverse effects; Blood Glucose/Blood Glucose/Blood Glucose/*drug effects ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy

  • Source: Scientific reports [Sci Rep] 2022 Jan 07; Vol. 12 (1), pp. 154. Date of Electronic Publication: 2022 Jan 07.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Report

Dulaglutide-related bullous pemphigoid in a patient with type 2 diabetes: A case report.

  • Authors : Fukuda G; Department of Diabetes, Metabolism and Endocrinology, International University of Health and Welfare Ichikawa Hospital, Chiba, Japan.; Yoshida T

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*complications ; Glucagon-Like Peptides/Glucagon-Like Peptides/Glucagon-Like Peptides/*analogs & derivatives ; Hypoglycemic Agents/Hypoglycemic Agents/Hypoglycemic Agents/*adverse effects

  • Source: Geriatrics & gerontology international [Geriatr Gerontol Int] 2019 Dec; Vol. 19 (12), pp. 1289-1290.Publisher: Japan Geriatrics Society Country of Publication: Japan NLM ID: 101135738 Publication

Record details

Read More Add to Saved list
×
  • 1-10 of  49 results for ""GLUCAGON-like peptides""